A Spinout Creates Another Spinout: How Public-Market Governance and Activist Pressure Reshaped Solventum

When Solventum was spun out of 3M in 2024, investors were presented with a familiar corporate promise: a standalone company, freed from the complexity of a conglomerate structure, could operate more efficiently, allocate capital more effectively, and ultimately create greater value for shareholders.

Two years later, Solventum’s decision to separate its Health Information Systems (HIS) business may be the clearest illustration yet of how that process is unfolding.

On August 5, the Minnesota-based healthcare company announced plans to pursue a separation of its HIS division, a healthcare software business that generates approximately $1.4 billion in annual revenue. Solventum stated that the move would sharpen its focus on its MedSurg and Dental Solutions businesses while allowing HIS to pursue its own strategic growth agenda. The company has not yet determined whether the business will be sold or spun off and expects the process to take approximately 12 to 18 months. [investors....ventum.com]

The announcement stands at the intersection of two developments that have shaped Solventum since its launch as an independent company: the governance and accountability demands that come with being a standalone public company and the influence of activist investor Trian Fund Management. [trianpartners.com], [trianpartners.com]

A Newly Independent Company Facing Public-Market Expectations

As a division of 3M, Solventum operated within a larger organization whose performance was judged as part of a diversified industrial portfolio.

As an independent public company, Solventum became directly accountable to shareholders for strategy, capital allocation, operating performance, and governance.

The company responded by adopting several governance practices commonly associated with public-company accountability. According to its 2026 proxy statement, Solventum has an independent board chair, independent board committees, majority voting in uncontested director elections, annual say-on-pay votes, shareholder outreach programs, and a planned transition to annual director elections beginning in 2028. [investors....ventum.com]

Management also launched a transformation strategy that included portfolio optimization and capital allocation initiatives. In 2025, Solventum completed the sale of its Purification & Filtration business and announced its first $1 billion share repurchase program. The company described those actions as part of a broader effort to improve strategic focus and long-term value creation. [investors....ventum.com]

Why Solventum Drew Activist Interest

Solventum also possessed several characteristics that have historically attracted activist investors. The company was newly independent, still defining its operating model and capital allocation priorities. Its portfolio included businesses with distinct characteristics, including medical products, dental products, and healthcare software. And as a recent spinout, investors were still debating how best to value the company and its individual business segments.

Trian Fund Management, founded by Nelson Peltz, Peter May, and Ed Garden, disclosed an ownership position of approximately 5% and became one of Solventum’s largest active shareholders. In January 2025, Trian publicly stated that it had already been engaging with management and the board regarding opportunities to improve performance and create shareholder value. [trianpartners.com], [boardroomalpha.com]

In subsequent public communications, Trian argued that Solventum could create additional value through three primary areas: improved operating performance, portfolio simplification, and enhanced capital allocation. The firm specifically advocated for a separation of the Health Information Systems business. [trianpartners.com]

Why Health Information Systems Became the Focus

One reason HIS became central to the conversation is that it differs substantially from Solventum’s other major businesses. While MedSurg and Dental Solutions are product-oriented healthcare businesses, HIS provides healthcare software, coding, and revenue-cycle management solutions. Solventum describes the unit as a healthcare software business whose products and services support healthcare reimbursement, clinician productivity, and value-based care initiatives. [investors....ventum.com], [investors....ventum.com]

Because HIS operates differently from Solventum’s medical products businesses, both management and Trian identified it as a logical candidate for strategic review.

Solventum stated that a separation would allow both businesses to pursue distinct growth agendas and capital allocation priorities. Trian publicly argued that simplifying the portfolio could unlock shareholder value and create a more focused company. [investors....ventum.com], [trianpartners.com]

Governance Structures Versus Governance Outcomes

Perhaps the most interesting aspect of the Solventum story is that the debate was not primarily about governance structures. Solventum already had many of the governance practices favored by institutional investors, including independent board leadership, independent committees, shareholder voting rights, and executive compensation oversight. [investors....ventum.com]

Trian’s criticism focused elsewhere. The firm’s public letters and statements argued that governance should be judged not only by structures but also by outcomes. Trian emphasized operating performance, portfolio decisions, capital allocation, and shareholder returns. [trianpartners.com], [boardmember.com]

In that sense, Trian’s campaign was less about changing Solventum’s governance structure and more about pushing the company to produce faster portfolio decisions, clearer strategic focus, and stronger shareholder value creation. [trianpartners.com], [boardmember.com]

This helps explain why the public debate centered on execution rather than board independence or governance mechanics.

The HIS Spinout as a Strategic and Governance Milestone

Viewed narrowly, the planned separation of HIS is a portfolio management decision.

Viewed more broadly, it is also an example of how shareholder expectations have evolved since the company’s spinout from 3M.

The transaction aligns with Solventum’s publicly stated portfolio optimization strategy. It also aligns with Trian’s public calls to simplify the company’s structure and separate HIS. [investors....ventum.com], [trianpartners.com]

The public record supports the conclusion that both Solventum management and Trian favored a separation of HIS. What the public record does not establish is whether the company would have pursued the transaction in the absence of Trian’s involvement. Neither party has publicly claimed that the decision was solely the result of activist pressure. [investors....ventum.com], [trianpartners.com]

What Investors Will Be Watching Next

The separation process is expected to take 12 to 18 months, and important questions remain unanswered, including whether HIS will ultimately be sold or spun off. [investors....ventum.com]

For investors, however, the larger question is likely to extend beyond the mechanics of the transaction itself. The separation will be evaluated based on whether it helps Solventum improve its strategic focus, allocate capital more effectively, and deliver stronger financial performance. Those are goals that management has emphasized through its transformation strategy and that Trian has emphasized through its activist campaign. [investors....ventum.com], [trianpartners.com]

The most notable takeaway may be that Solventum’s evolution since its 2024 spinout has not been driven by a single force. Rather, it reflects the combined influence of public-market accountability, governance reforms, portfolio optimization efforts, and shareholder activism. The planned separation of Health Information Systems is the most visible example so far of how those forces have converged around a more focused company. [investors....ventum.com], [trianpartners.com], [trianpartners.com

See the boardroom simulation Selling a Business Case Study (TM)